Rahmannia et al., 2021 - Google Patents
The effect of RNA and non-RNA vaccines in variants of Covid-19: A narrative reviewRahmannia et al., 2021
View PDF- Document ID
- 1854599979827492975
- Author
- Rahmannia M
- Abadi S
- Hasani A
- Khanali F
- Vosoughian F
- Mirzaei R
- ESMAEILI H
- Publication year
- Publication venue
- Pakistan J Medical Health Sci
External Links
- 229960005486 vaccines 0 title abstract description 211
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Awadasseid et al. | Current advances in the development of SARS-CoV-2 vaccines | |
| Jiang et al. | Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy | |
| Martinez-Flores et al. | SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants | |
| Kaur et al. | COVID-19 Vaccine: A comprehensive status report | |
| Zhou et al. | Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies | |
| Ghaebi et al. | Vaccine development and therapeutic design for 2019‐nCoV/SARS‐CoV‐2: Challenges and chances | |
| Zacks et al. | Encephalitic alphaviruses | |
| Cao et al. | A phase 1 randomized open-label clinical study to evaluate the safety and tolerability of a novel recombinant hepatitis E vaccine | |
| Marfe et al. | Effectiveness of COVID-19 vaccines and their challenges | |
| Milligan et al. | Defining a correlate of protection for chikungunya virus vaccines | |
| Lukashevich et al. | Lassa virus diversity and feasibility for universal prophylactic vaccine | |
| Cao et al. | A single vaccine protects against SARS-CoV-2 and influenza virus in mice | |
| US20220249651A1 (en) | Universal vaccines against immunogens of pathogenic organisms that provide organism-specific and cross-group protection | |
| Li et al. | Analysis of the protective efficacy of approved COVID-19 vaccines against various mutants | |
| Samaddar et al. | Pathophysiology and potential therapeutic candidates for COVID-19: a poorly understood arena | |
| KR20210123155A (en) | Use of RBD as diagnostic, treatment or vaccine of COVID-19 | |
| Freppel et al. | Pathogenicity and virulence of chikungunya virus | |
| WO2021206638A1 (en) | Vaccine and/or antibody for viral infection | |
| Harne et al. | SARS-CoV-2 infection and immune responses | |
| Toyama et al. | DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study | |
| Ying et al. | A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ. 1.1 and XBB. 1.5 infection and disease in mice and hamsters | |
| US20160235837A1 (en) | THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR MIDDLE EAST RESPIRATORY SYNDROME VIRUS (MERS CoV) | |
| Gong et al. | Chloroform-methanol residue of Coxiella burnetii markedly potentiated the specific immunoprotection elicited by a recombinant protein fragment rOmpB-4 derived from outer membrane protein B of Rickettsia rickettsii in C3H/HeN mice | |
| Rahmannia et al. | The effect of RNA and non-RNA vaccines in variants of Covid-19: A narrative review | |
| Jeyanthi et al. | COVID-19 outbreak: An overview and India’s perspectives on the management of infection |